TrialJournal of acquired immune deficiency syndromes (1999)2021

Brief Report: Improvement in Metabolic Health Parameters at Week 48 After Switching From a Tenofovir Alafenamide-Based 3- or 4-Drug Regimen to the 2-Drug Regimen of Dolutegravir/Lamivudine: The TANGO Study.

Jean van Wyk et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.